Metachromatic Leukodystrophy Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032) – DelveInsight | Takeda, Denali Therapeutics, Homology Medicines, Passage Bio, ArmaGen

 Breaking News
  • No posts were found

Metachromatic Leukodystrophy Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032) – DelveInsight | Takeda, Denali Therapeutics, Homology Medicines, Passage Bio, ArmaGen

September 21
21:32 2023
Metachromatic Leukodystrophy Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032) -  DelveInsight | Takeda, Denali Therapeutics, Homology Medicines, Passage Bio, ArmaGen
Delveinsight Business Research LLP
As per DelveInsight, the Metachromatic Leukodystrophy Market is anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases of Metachromatic Leukodystrophy, the improvement in the research and development activities, and the launch of new therapies in the market. The pipeline of Metachromatic Leukodystrophy (MLD) possesses a few potential key players, such as Takeda, Talaris, and others.

DelveInsight’s “Metachromatic Leukodystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metachromatic Leukodystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Metachromatic Leukodystrophy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metachromatic Leukodystrophy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Metachromatic Leukodystrophy: An Overview

According to the National Institute of Health (NIH), Metachromatic Leukodystrophy (MLD) is a rare inherited disorder characterized by the accumulation of fats called sulfatides in cells. This accumulation especially affects cells in the nervous system that produce myelin, the substance that insulates and protects nerves. Nerve cells covered by myelin make up a tissue called white matter. This condition is called metachromatic leukodystrophy because when viewed under a microscope, sulfatide accumulation in cells appears as granules that are colored differently than other cellular material (metachromatic).

MLD is caused due to mutations in the ARSA gene, which provides instructions for making the enzyme arylsulfatase A. This enzyme is located in cellular structures called lysosomes, which are the cell’s recycling centers. Within lysosomes, arylsulfatase A helps break down sulfatides. A few individuals with metachromatic leukodystrophy have mutations in the PSAP gene. This gene provides instructions for making a protein that is broken up (cleaved) into smaller proteins that assist enzymes in breaking down various fats. One of these smaller proteins is called saposin B; this protein works with arylsulfatase A to break down sulfatides.

Metachromatic Leukodystrophy Market Key Facts

  • According to the National Organization for Rare Diseases (NORD), the true prevalence rate of MLD is unknown but is estimated to be between 1 in 40,000 and 1 in 160,000.

  • As per the MalaCards Human Disease Database, MLD is inherited in an autosomal recessive manner with a prevalence of 1-9 per 100,000 in Europe, the United States, and worldwide and the age of onset of different forms of MLD varies.

  • According to Natalia et al. study titled “Arylsulfatase A Deficiency” stated that the onset of Late-infantile, Juvenile MLD, and Adult MLD is before age 30 months, between age 30 months and 16 years and after age 16 years respectively.

Metachromatic Leukodystrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metachromatic Leukodystrophy pipeline therapies. It also thoroughly assesses the Metachromatic Leukodystrophy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Metachromatic Leukodystrophy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Metachromatic Leukodystrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Metachromatic Leukodystrophy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Metachromatic Leukodystrophy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Metachromatic Leukodystrophy Epidemiology, Segmented as –

  • Prevalent Population of Metachromatic Leukodystrophy (MLD) in the 7 MM [2019-2032]

  • Age-specific Prevalent Population of Metachromatic Leukodystrophy (MLD) in the 7 MM {Late infantile form, Juvenile form, and Adult form} [2019-2032]

  • Diagnosed and Treatable Cases of Metachromatic Leukodystrophy (MLD) in the 7 MM [2019-2032]

Metachromatic Leukodystrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Metachromatic Leukodystrophy market or expected to be launched during the study period. The analysis covers the Metachromatic Leukodystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Metachromatic Leukodystrophy drugs based on their sale and market share.

The report also covers the Metachromatic Leukodystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Metachromatic Leukodystrophy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Metachromatic Leukodystrophy Market Will Evolve and Grow by 2032 @

Metachromatic Leukodystrophy Therapeutics Analysis

Currently, the market holds no effective treatment to reverse the deterioration and loss of function that MLD causes. Treatment for the condition focuses on managing symptoms and improving your quality of life i.e. it’s generally supportive in nature. The management of MLD can be done by using medications, physical, occupational, and speech therapy, and nutritional assistance can help the patients suffering from MLD. Bone marrow transplantation may delay the progression of the disease in some infantile-onset cases.

Medications, mainly painkillers, can be used which may reduce the signs and symptoms and thereby relieve muscle pain. The signs and symptoms of MLD that can be resolved using medicines include such as behavioral problems, seizures, difficulty with sleeping, gastrointestinal issues, infection, and pain. Physical therapy can help by curing stiffness in the joints to get short-term relief. One can rely on a wheelchair, walker, or other assistive devices as the condition progresses.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Metachromatic Leukodystrophy. Currently, Orchard Therapeutics is leading the therapeutics market with its Metachromatic Leukodystrophy drug candidates in the most advanced stage of clinical development.

Metachromatic Leukodystrophy Companies Actively Working in the Therapeutics Market Include

  • Takeda

  • Denali Therapeutics

  • Orchard Therapeutics

  • Homology Medicines

  • Passage Bio

  • ArmaGen Technologies

And Many Others

Emerging and Marketed Metachromatic Leukodystrophy Therapies Covered in the Report Include:

  • OTL-200: Orchard Therapeutics

OTL-200 (autologous CD34+ cell-enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase-A (ARSA) gene), referred to as Libmeldy in the European Union, is an ex vivo autologous hematopoietic stem cell gene therapy approved by the European Medicines Agency (EMA) in 2020. OTL-200 is an investigational therapy that has not been approved by the U.S. Food and Drug Administration (FDA) or any other health authority.

  • TAK-611: Takeda

TAK-611, a recombinant cerebroside sulfatase is being developed by Takeda as an enzyme replacement therapy for the treatment of metachromatic leukodystrophy (MLD), a rare hereditary disease characterized by the accumulation of toxic lipids that destroy the myelin sheath surrounding neurons. It is currently in the phase II stage of development for metachromatic leukodystrophy.

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Metachromatic Leukodystrophy Competitive Intelligence Analysis

4. Metachromatic Leukodystrophy Market Overview at a Glance

5. Metachromatic Leukodystrophy Disease Background and Overview

6. Metachromatic Leukodystrophy Patient Journey

7. Metachromatic Leukodystrophy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Metachromatic Leukodystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Metachromatic Leukodystrophy Unmet Needs

10. Key Endpoints of Metachromatic Leukodystrophy Treatment

11. Metachromatic Leukodystrophy Marketed Therapies

12. Metachromatic Leukodystrophy Emerging Drugs and Latest Therapeutic Advances

13. Metachromatic Leukodystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Metachromatic Leukodystrophy Market Outlook (In US, EU5, and Japan)

16. Metachromatic Leukodystrophy Companies Active in the Market

17. Metachromatic Leukodystrophy Access and Reimbursement Overview

18. KOL Views on the Metachromatic Leukodystrophy Market

19. Metachromatic Leukodystrophy Market Drivers

20. Metachromatic Leukodystrophy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.


Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Unlock key insights and innovation in the healthcare industry with our cutting-edge market research services, paving the way for informed decisions and competitive advantage in this rapidly evolving industry @ Medical Device Consulting Services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles